Panobinostat lactate Drug Asset Due Diligence Report 2026

This Panobinostat lactate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

167

Registered trials

149

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Panobinostat lactate can convert its Small molecule drug profile and HDACs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Panobinostat lactate (query alias: panobinostat)
Modality / target	Small molecule drug; HDACs; HDAC inhibitors, Epigenetic drug
Highest global status	Approved
Originator	Novartis Pharma AG
Active developers	Pharma& Schweiz GmbH, Secura Bio, Inc., Biodexa Pharmaceuticals Plc

The MCP disease footprint includes Multiple Myeloma, Medulloblastoma, Acute Chest Syndrome. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05725200	Phase 2	Recruiting	40	Pre-Screening: Obtain a combined pharmacogenomic profile which can be used to provide a MTB-nominated treatment
NCT06240520	Phase 1/2	Unknown status	49	Cell-associated HIV RNA
NCT05324501	Phase 1	Terminated	4	Safety of MTX110 administered by CED

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Feasibility Study Examining the Use of Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat Administration in Children With Progressive Diffuse Midline Glioma (DMG)

Phase 1; n=5; evaluation: not stated. Reported fields: -; -; Number of Adverse Events = 31 adverse events

CLINICAL EXPERIENCE WITH HDAC INHIBITOR-BASED PROTOCOLS IN MECOM-REARRANGED ACUTE MYELOID LEUKEMIA

Not Applicable; n=562; evaluation: not stated. Reported fields: CR = 56 % ; CR = 56 % ; CR = 56 %

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma

Phase 2; n=83; evaluation: not stated. Reported fields: PFS = 38 Participants ; PFS = 24 Participants ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Panobinostat lactate addresses Multiple Myeloma, Medulloblastoma, Acute Chest Syndrome. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-02-18	Secura Bio obtains global rights to Novartis' Farydak for relapsed or refractory multiple myeloma.	Approved	Financial terms not disclosed
2019-01-29	China Medical System Holdings sign a License, Collaboration and Distribution Agreement with Midatech Pharma and Make Equity Investment in It	Preclinical	Financial terms not disclosed
2017-06-07	Midatech to Develop Novartis’ Panobinostat for Treating Childhood Brain Cancer	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO